A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea

BACKGROUND: Tixagevimab and cilgavimab (Evusheld) administration is a recommended strategy for unvaccinated patients with immunocompromised conditions and severe allergic reaction conditions to protect high-risk individuals and control the coronavirus disease 2019 (COVID-19) epidemic. We estimated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jo, Youngji, Kim, Sun Bean, Jung, Jaehun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427216/
https://www.ncbi.nlm.nih.gov/pubmed/37582500
http://dx.doi.org/10.3346/jkms.2023.38.e250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427216/
https://www.ncbi.nlm.nih.gov/pubmed/37582500
http://dx.doi.org/10.3346/jkms.2023.38.e250

Ejemplares similares